OncoSynergy
2011
FOUNDED
PRIVATE
STATUS
Series A1
LATEST DEAL TYPE
$1.15M
LATEST DEAL AMOUNT
5
INVESTORS
Description
Developer of oncology therapeutics designed to radically improve outcomes for patients with unmet needs in oncology. The company's therapeutics include a new class of oncology called Resistance Mechanism Inhibitors (RMIs), that feature multiple simultaneous mechanisms of action and synergy in combination with other treatments, including immunotherapies in a preclinical model, enabling oncologists to treat haematological cancers easily.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- Greenwich, CT
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore OncoSynergy’s full profile, request a free trial.
OncoSynergy Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Early Stage VC (Series A1) | 02-Aug-2019 | $1.15M | 000.00 | 000.00 | Completed | Generating Revenue |
| 5. Seed Round | 14-May-2018 | 0000 | 000.00 | 0000 | Completed | Generating Revenue |
| 4. Accelerator/Incubator | 19-May-2017 | 000.00 | Completed | Generating Revenue | ||
| 3. Accelerator/Incubator | 000.00 | Completed | Generating Revenue | |||
| 2. Merger/Acquisition | 05-Apr-2016 | Cancelled | Generating Revenue | |||
| 1. Seed Round | 28-Jun-2015 | $10.2M | $10.2M | Completed | Generating Revenue |
OncoSynergy Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series A | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
OncoSynergy Competitors (42)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kesios | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 0000 | 000000 - 000 | 0000 |
| 00000000 | Venture Capital-Backed | Tübingen, Germany | 000 | 00000 | 00000000000 | 00000 |
| 000 0000000000000 | Venture Capital-Backed | Chester, United Kingdom | 00 | 000.00 | 00000000000 | 000.00 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 0000 000000000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000000 | 00000 |
OncoSynergy Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Connecticut Innovations | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Korea Information & Communications Company | Corporation | Minority | 000 0000 | 000000 0 | ||
| NLabs | Family Office | Minority | 000 0000 | 000000 0 | ||
| JLABS | Accelerator/Incubator | 000 0000 | 000000 0 | |||
| California Institute for Quantitative Biosciences | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |
OncoSynergy Executive Team (3)
OncoSynergy Board Members (5)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Allen Salmasi Ph.D | Self | Chairman | 000 0000 | |
| Amanda Hayward Ph.D | Connecticut Innovations | Board Member | 000 0000 | |
| Anne-Marie Carbonell | OncoSynergy | Co-Founder, Chief Medical Officer & Board Member | 000 0000 | |
| Hen-Suh Park Ph.D | OncoSynergy | Board Member | 000 0000 | |
| Robert Dunkle | OncoSynergy | Board Member | 000 0000 |